ADVA
4.11.2021 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has set an industry record by transporting 800Gbit/s farther than ever before over a live network. Using the ADVA FSP 3000 TeraFlex™ CoreChannel™ , FUNET’s succeeded in transmitting data at 800Gbit/s on links exceeding 2,000km. The field trial shows how network operators can leverage new value in existing large-scale infrastructure and how FUNET can empower the Nordics’ academics and scientists to achieve even more. Harnessing 140GBd sub-carrier technology, ADVA’s new CoreChannel™ sled leverages 150GHz channel spacing, enabling TeraFlex™ to deliver the market’s longest reach for a single-channel 800Gbit/s solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005050/en/
“ADVA’s FSP 3000 TeraFlex™ CoreChannel™ at 800Gbit/s speed delivered impressive reach during our tests and was stable throughout the month-long test period when we ran it on our nationwide ADVA open line system . The new 800Gbit/s channel technology will give us more flexibility to choose optimum modulation per use case to improve spectral efficiency. And, more importantly, it maps efficiently to 400GbE client services,” said Jani Myyry, senior network specialist, CSC/FUNET. “This field trial demonstrates that our network can smoothly support future requirements and deliver even more to our users in the Finnish research and education community. It also will strengthen our confidence that the first multi-Terabit services we aim to deliver early next year together with other Nordic research and education networks can be implemented successfully.”
With the addition of the new CoreChannel™ sled , ADVA’s FSP 3000 TeraFlex™ is the industry’s most efficient high-capacity open optical terminal for all applications from metro to submarine links. Now trials in the ultra-long-haul FUNET transport system have proven its compatibility with deployed infrastructure and shown that it offers excellent performance in a live flexgrid network built with multi-degree ROADMs and RAMAN amplifiers. TeraFlex™ CoreChannel™ also delivers industry-leading SNR requirements, making it resilient to transmission impairments. Featuring multi-rate client support, the CoreChannel™ sled can also transport any mix of 400GbE, 100GbE and 10GbE services, protecting investment and providing complete flexibility.
“It’s fantastic to see our FSP 3000 TeraFlex™ with CoreChannel™ sled pass this major test with such flying colors. Even over the FUNET network’s longest distances, the solution surpassed expectations and showed how incredible speeds are now possible at the lowest possible cost per bit per kilometer,” commented Cornelius Fürst, director, product line management, ADVA. “One of the reasons our FSP 3000 TeraFlex™ CoreChannel™ is able to provide such great long-haul performance is that it carries data at 800Gbit/s using a 150GHz window. Not only does this help to reduce complexity and avoid stranded bandwidth, but it also makes the technology future-proof. 150GHz is the channel spacing that offers the best balance between fiber capacity and optical reach. That’s why it’s gaining traction across the industry and why our open FSP 3000 TeraFlex™ CoreChannel™ sled is ready for new innovation further down the line.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About CSC – IT Center for Science Ltd.
CSC – IT Center for Science is a Finnish center of expertise in information technology owned by the Finnish state and higher education institutions. We provide internationally high-quality ICT expert services for higher education institutions, research institutes, culture, public administration and enterprises. For more information, please visit www.csc.fi
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
